Eversheds has advised Mandarin Capital Partners Secondary S.C.A. SICAR (a private equity fund), Health Holding Company S.r.l. (an industrial holding) and Giorgio Moretti (owner of HHC and CEO of Dedalus Group), on a 60% acquisition in Dedalus Holding S.p.A. by HealthLux S.A., an investment vehicle of Ardian LBO Fund B SLP (a private equity fund).

Dedalus Group is a leading player in healthcare software in Italy and one of the largest in Europe, with a presence in 25 countries. Ardian will acquire a 14% stake from Hutton Collins Partners and Three Hills Capital Partners, 35.59% from Mandarin and 10.41% from HHC.

Following completion of the deal the Dedalus Group will be owned 60% by Ardian and 40% by HHC. Giorgio Moretti will maintain his role as CEO of the Dedalus Group.

Before signing between Ardian and HHC (and the other shareholders of Dedalus Holding), the Dedalus Group acquired Ghemos S.r.l., the controlling company of Noemalife S.p.A, a company listed on the Milan Stock Exchange and launched a public tender offer to acquire the remaining equity of Noemalife.

The public tender offer (and consequential delisting of Noemalife) is expected to be completed before completion with Ardian.

Partner Marco Franzini and senior associate Alessandro Vischi advised on the deal, with the support of partner Sebastiano Sciliberto on tax aspects and partner Alessandro Greco for the antitrust filing.